Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
暂无分享,去创建一个
[1] C. Sternberg,et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial , 2007 .
[2] H. Scher,et al. The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer , 2007, Clinical Cancer Research.
[3] Elisabeth Brambilla,et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.
[4] I. Tannock,et al. Management of advanced prostate cancer after first-line chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Sternberg. Satraplatin in the treatment of hormone‐refractory prostate cancer , 2005, BJU international.
[6] L. Collette,et al. Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer , 2005, Oncology.
[7] C. Nabhan. Chemotherapy for advanced prostate cancer. , 2005, The New England journal of medicine.
[8] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[9] Suzanne F. Jones,et al. Phase I Study of JM-216 (an Oral Platinum Analogue) in Combination with Paclitaxel in Patients with Advanced Malignancies , 2002, Investigational New Drugs.
[10] T. Buclin,et al. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. , 2003, Anticancer research.
[11] H. Groen,et al. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. , 2002, Biochemical pharmacology.
[12] G. Auclerc,et al. Management of advanced prostate cancer. , 2000, The oncologist.
[13] C. Giandomenico,et al. Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.
[14] I. Judson,et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Eisenberger,et al. Chemotherapy for Advanced Prostate Cancer , 1991 .
[16] M. Troner,et al. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial. , 1986, Cancer treatment reports.
[17] R. Melzack. The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.